Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 6/20 | 0.67 |
| ▸ | CES1 | P23141 | 6/20 | 0.67 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29775631 | 1.00 | CES2 (0.67) | CES2CES1BCHEKMT2AMAOB | |
| SCHEMBL2315628 | 0.82 | CES2 (0.50) | CES2CES1BCHEKMT2AMAOB | |
| SCHEMBL2601627 | 0.82 | CES2 (0.45) | CES2CES1KMT2AMAOBMAOA | |
| SCHEMBL26771499 | 0.82 | CES2 (0.50) | CES2CES1BCHEKMT2AMAOB | |
| SCHEMBL4621035 | 0.82 | CES2 (0.45) | CES2CES1BCHEKMT2AMAOB | |
| SCHEMBL8281191 | 0.82 | CES2 (0.45) | CES2CES1BCHEKMT2AMAOB | |
| SCHEMBL116280 | 0.81 | CES2 (0.45) | CES2CES1KMT2AMAOBMAOA | |
| SCHEMBL2827111 | 0.80 | CES2 (0.48) | CES2CES1BCHEKMT2AMAOB | |
| SCHEMBL29741520 | 0.80 | CES2 (0.48) | CES2CES1BCHEKMT2AMAOB | |
| SCHEMBL1760850 | 0.80 | CES2 (0.73) | CES2CES1BCHEALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| US-20140371464-A1 | PROCESS FOR THE PREPARATION OF CHIRAL ISOXAZOLINE AZETIDINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC | 2014-12-18 | — | — | US | claimed |
| EP-2809667-A1 | PROCESS FOR THE PREPARATION OF CHIRAL ISOXAZOLINE AZETIDINE DERIVATIVES AS ANTIPARASITIC AGENTS | Zoetis LLC (US) | 2014-12-10 | — | — | EP | claimed |
| WO-2013116236-A1 | PROCESS FOR THE PREPARATION OF CHIRAL ISOXAZOLINE AZETIDINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS LLC (US) | 2013-08-08 | — | — | WO | claimed |
| JP-7101921-A | — | — | None | — | — | JP | disclosed |
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | ASTRAZENECA AB (SE) | 2025-09-02 | — | — | US | disclosed |
| US-20240383866-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | ASTRAZENECA AB (SE) | 2024-11-21 | — | — | US | disclosed |
| US-20240199558-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | US | disclosed |
| WO-2024083933-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX 3CR1 | ASTRAZENECA AB (SE) | 2024-04-25 | — | — | WO | disclosed |
| EP-3798217-B1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-02-22 | — | — | EP | disclosed |
| CN-115612045-A | Isatin-aromatic hydrocarbon copolymer, electrolyte solution thereof, and preparation method and application of ion exchange membrane | 大连理工大学 | 2023-01-17 | — | — | CN | disclosed |
| CN-109563085-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | disclosed |
| US-20070272003-A1 | 2-(2-{2-[2-(2-{2-[2-(11-mercaptoyldisulfanyl-undecyloxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy} acetic acid pentafluorophenyl ester; poly(ethylene oxide) groups resist nonspecific adsorption and enhance the specific affinity interactions | IMEC (BE) | 2007-11-29 | — | — | US | disclosed |
| US-20070272003-A1 | 2-(2-{2-[2-(2-{2-[2-(11-mercaptoyldisulfanyl-undecyloxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy} acetic acid pentafluorophenyl ester; poly(ethylene oxide) groups resist nonspecific adsorption and enhance the specific affinity interactions | IMEC (BE) | 2007-11-29 | — | — | US | disclosed |
| WO-2007081335-A1 | THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| EP-1448193-A4 | THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS | MERCK & CO INC (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1448193-A1 | THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS | Merck & Co., Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045382-A1 | THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS | MERCK & CO., INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| JP-H07101921-A | OPTICALLY ACTIVE TRIFLUOROMETHYLBENZYL ALCOHOL DERIVATIVE AND ITS PRODUCTION | CHISSO CORP | 1995-04-18 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199558-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | CX3CR1, CCR2, CCR5 | CES2 3829/4885CES1 4432/4885BCHE 4871/4885 |
| US-20240383866-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | CX3CR1, CCR2, CCR5 | CES2 3829/4885CES1 4432/4885BCHE 4871/4885 |
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | CX3CR1, CCR2, CCR5 | CES2 3829/4885CES1 4432/4885BCHE 4871/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | CES2 4820/4885CES1 3698/4885BCHE 3227/4885 |
| US-20140371464-A1 | PROCESS FOR THE PREPARATION OF CHIRAL ISOXAZOLINE AZETIDINE DERIVATIVES AS ANTIPARASITIC AGENTS | RDX, CYP2C9, CYP1A2 | CES2 376/4885CES1 419/4885BCHE 422/4885 |
| US-20070272003-A1 | 2-(2-{2-[2-(2-{2-[2-(11-mercaptoyldisulfanyl-undecyloxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy} acetic acid pentafluorophenyl ester; poly(ethylene oxide) groups resist nonspecific adsorption and enhance the specific affinity interactions | EBPL, AEBP2, NAPA | CES2 920/4885CES1 3935/4885BCHE 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.